Compare Expeditors International of Wshngtn Inc (EXPD) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Incyte Corporation — how do they compare? Expeditors International of Wshngtn Inc trades at $177.4 (market cap $23.04B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Expeditors International of Wshngtn Inc and Incyte Corporation are close in size by market cap, and Expeditors International of Wshngtn Inc pays a 0.91% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| EXPD | INCY | |
|---|---|---|
Market Cap | $23.04B | $24.54B |
Sector | Industrials | Health |
52-Week High | $182.80 | $129.93 |
52-Week Low | $113.13 | $81.61 |
Enterprise Value | $22.57B | $20.04B |
Dividend Yield | 0.91% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
